Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The placental pathology in Coronavirus disease 2019 infected mothers and its impact on pregnancy outcome

Bharti Joshi a,1, Anadeep Chandi a,*,1, Radhika Srinivasan b, Shiv Sajan Saini c, G.R.V. Prasad a, G.D. Puri d, Ashish Bhalla a, Vanita Suri a, Rashmi Bagga a

a Department of Obstetrics and Gynecology, PGIMER, Nehru Block, Sector 12, Chandigarh, 160012, India
b Department of Cytology & Gynecological Pathology, PGIMER, Research Block A, Sector 12, Chandigarh, 160012, India
c Division of Neonatology, Department of Pediatrics Medicine, PGIMER, Nehru Block, Sector 12, Chandigarh, 160012, India
d Department of Obstetrics and Gynecology, PGIMER, Nehru Block, Sector 12, Chandigarh, 160012, India

* Corresponding author. Department of Obstetrics and Gynecology, PGIMER, Nehru Block, Sector 12, Chandigarh, 160012, India.
E-mail addresses: drbhartijoshi09@gmail.com (B. Joshi), ana.chandi@gmail.com (A. Chandi), drsradhika@gmail.com, drsradhika@gmail.com (R. Srinivasan), sajansaini1@gmail.com (S.S. Saini), prasad.grv@pgimer.edu.in (G.R.V. Prasad), puri.gd@pgimer.edu.in (G.D. Puri), bhalla.ashish@pgimer.edu.in (A. Bhalla), surivanita@yahoo.co.in (V. Suri), bagga.rashmi@pgimer.edu.in (R. Bagga).
1 Dr. Bharti Joshi and Dr. Anadeep Chandi has equal contribution to the study.

Contents lists available at ScienceDirect
Placenta journal homepage: www.elsevier.com/locate/placenta

ABSTRACT

Introduction: This study aims at observing placental pathologies in COVID-19 infected women, and analyzing its impact on pregnancy outcome.

Method: This is a descriptive-analytical study done at a tertiary centre of Northern India. All COVID-19 positive pregnant women with gestational age ≥20 weeks, with placental histopathological reporting, were included in this study. A total of 173 COVID-19 pregnant women were included in the study.

Results: Placental abnormalities were noticed in 49-16% of total 179 placenta examined. Maternal vascular malperfusion (27.93%) was the most observed placental pathology followed by villous fibrin deposits (22.90%), fetal vasculopathy (16.75%), and acute inflammation (6.70%). Stillbirths were 22 and NICU admissions were seen in 50 neonates. Abnormal placental abnormalities led to higher stillbirths (p value 0.011) and lower Apgar scores at 1 and 5 min (p-value 0.028; p-value 0.002, respectively). Intervillous fibrin deposits had higher risk associated with lower Apgar score at 1 and 5 min [RR 2.05 (95% CI 1.21–3.48, p-value 0.010) and RR 5.52 (95% CI 2.58–11.81, p-value <0.001), respectively]. RP clot/hemorrhage was also associated with lower Apgar score at 1 and 5 min [RR 2.61 (95% CI 1.52–4.49, p-value 0.002) and RR 3.54 (95% CI 1.66–7.55, p-value 0.001), respectively].

Discussion: Placental abnormalities in COVID-19 infection were associated with significant higher incidence of unexplained stillbirths, and lower Apgar scores. Although, this is the largest descriptive-analytical study done so far, comparative studies are required to draw a clear conclusion regarding the impact of COVID-19 infection on human placenta and its effect on pregnancy outcomes.

1. Introduction

Since the outbreak of the SARS-CoV-2 virus, also known as Coronavirus disease 2019 (COVID-19), the world has seen more than 197 million infections and 4.2 million deaths globally [1]. The immuno-compromised state of pregnancy makes it more susceptible to viral respiratory infections [2]. The placenta which forms the maternal-fetal interface, has an attenuated immune response and is known to host several viral infections [3–6]. Adverse maternal environment like hypoxia, inflammatory activation, and increased thrombotic events secondary to COVID-19 infection makes placenta a potential target for the pathological insult which may lead to adverse pregnancy outcomes [7,8]. Although several studies mention various placental features in COVID-19 infection, no consensus regarding characteristic pathological findings has emerged so far [9–11]. Also, the clinical relevance of the placental pathology seen in COVID-19 infection is yet to be established. In this research article, we aim at studying the placental pathologic findings in women with COVID-19 infection and analyzing its impact on...
the pregnancy outcome.

2. Materials and methods

2.1. Study design

This is a descriptive-analytical study conducted from 1st July 2020 to 30th June 2021 at the Postgraduate Institute of Medical Sciences and Research (PGIMER), Chandigarh, India—a tertiary care institute that has a dedicated COVID-19 obstetrics team along with separate portal ultrasound machine with doppler facilities. The data was collected on a prospective basis from 28th August 2020 onwards. There was no funding source for this study.

2.2. Cases selection

All pregnant women with COVID-19 infection confirmed by nasopharyngeal swabs specimens tested with SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) assay or GeneXpert Dx Xpress SARS-CoV-2 RT-PCR assay, who delivered at our center were enlisted for the study. The placenta of these women were sent to the department of pathology and virology for histopathological examination and COVID-19 RT-PCR testing, respectively. All those COVID-19 infected women who delivered at or more than 20 weeks of gestation, and in whom the placental examination was reported, were included in the study. The maternal demography characteristics, obstetrical complications, COVID-19 disease severity, mode of delivery, maternal mortality, and neonatal details were recorded for these women. Neonatal growth restriction was considered when the birth weight was below the 10th percentile according to the growth chart.

2.3. Placental morphologic data collection

As per the institute’s protocol, all placentae from the COVID-19 mothers were collected soon after the delivery. They were fixed in 10% buffered formaldehyde, labelled, and transported to the department of pathology and virology at PGIMER, Chandigarh. The placental examination was performed and documented as per the Amsterdam guidelines [12]. The placental morphological reports were then uploaded on the institute’s software system named HIS- Laboratory Information System (LIS) software module, specially assigned to the department of pathology for data recording.

The reports of the study women were searched from the HIS-LIS software system with the help of their name and hospital registration number. The placental weight to baby weight (PW/BW) ratio was calculated by dividing the placenta weight and the birth weight. In the case of twins, it was calculated by dividing the placenta weight and the total birth weight (the sum of both twin’s birth weight). The growth percentiles of placental weight and PW/BW ratio were calculated as per the nomograms [13,14]. The histopathologic parameters were searched and recorded as per the Amsterdam guidelines. Based on the histopathology of placentae, 2 groups were formed. Group 1 included all the COVID-19 women with the normal placental examination, and Group 2 included all the COVID-19 women with the abnormal placental examination. The maternal clinical characteristics and neonatal outcomes in each group were compared and analysed. The placentae that were sent for COVID-19 infection by RT-PCR testing in the department of virology were also followed and recorded.

2.4. Statistical analysis

The data were analysed using Statistical Package for the Social Sciences (SPSS version 20, IBM SPSS Incorporated, Chicago, IL, USA). Numerical data are presented as the mean and standard deviation (SD), or the median, minimum, and maximum (range), when appropriate. Categorical data are presented as relative and absolute frequencies. For quantitative variables, the group 1 and 2 were compared with the Mann-Whitney U test or Student’s t-test, depending on the data characteristics. The associations between qualitative categorical variables were investigated using Chi-square or Fisher’s exact tests, when appropriate. Risk assessment was performed by calculating the relative risk (RR) with a 95% confidence interval (CI). The statistical numbers were rounded to two decimal places for mean, standard deviation, percentages, relative risk, and 95% confidence interval. The p-values were rounded to three decimal places. A p-value <0.050 was considered to indicate statistical significance, and a p-value of <0.001 was considered highly significant.

3. Results

3.1. Clinical characteristics of COVID-19 positive mothers

A total of 332 COVID-19 positive pregnant women with ≥20-week gestation reported to our institute from 1st July 2020 to 30th June 2021. Out of these, placental morphologic examination and reporting were done for 173 COVID-19 mothers. The demographic characteristics and obstetric details of these mothers are represented in Table 1. The mean and median age of the COVID-19 positive mothers was 28.87 ± 4.84 and 29 years, respectively. Out of 173 COVID-19 mothers, only 26 were symptomatic for COVID-19 infection, 15 had severe COVID-19 disease, and six maternal mortalities were seen due to the COVID-19 complications. The interval between the diagnosis of COVID-19 infection and the delivery of the women ranged from 0 to 42 days with a median of 1 day (IQR 0–2 days). A total of 160 mothers had singleton gestations and 13 mothers had twin pregnancies. Out of 173 cases, 4 abortions (baby birth weight <500 g and gestation age <24 weeks) were observed. The mean and median gestational age at delivery was 34.95 ± 4.29 and 36 weeks, respectively. A total of 90 preterm deliveries were noted, out of which 55 were early preterm and 35 were late preterm deliveries. The term deliveries were seen in seventy-nine COVID-19 women. Obstetrical complications like gestational diabetes were seen in 22 women, 26 women were diagnosed with premature rupture of membranes (PROM), and 49 women had hypertensive disorders of pregnancy (34 had pre-eclampsia, 12 had gestational hypertension, and 3 had chronic hypertension). The fetal growth restriction (FGR) was seen in 19 women, antepartum hemorrhage (APH) in 24, and intrahepatic cholestasis of pregnancy (ICP) was reported in 7 women. Vaginal delivery was seen in 57 women and 112 women underwent cesarean section. A total of 186 babies were born to 173 COVID-19 mothers. Ninety-two were male and 94 were female babies. Congenital malformations were reported in 14 babies and 22 babies were stillborn (including abortion cases). Mean and median baby weight at birth was 2156.15 ± 820.88 and 2202 g. Mean and median placental weight was 465.71 ± 171.35 and 461 g. A total of forty-five babies were born with an Apgar score of <7 and 141 babies had an Apgar score of ≥7 at 1 min of life. The Apgar score at 5 min was <7 in 27 babies, and ≥7 in 159 babies. Sixty-three babies were small for gestational age (SGA), 109 were appropriate for gestational age (AGA), and 14 were large for gestational age (LGA) babies. Neonatal intensive care unit (NICU) admissions were seen for 50 neonates out of 164 live babies.

3.2. Placental morphologic features

A total of 179 placentae of COVID-19 mothers were examined and reported. Out of 13 twin placentae, 8 were dichorionic diamniotic (DCDA), 4 were monochorionic diamniotic (MCDA), and one placenta was fused to a single mass when received by the department of pathology, thereby, choriality was not established. Out of 8 dichorionic diamniotic (DCDA) placentae, placental examination and reporting were done separately for each twin in 6 cases, however in 2 cases, the twin placentae were fused in the center, and combined examination and reporting was done. Normal histopathological examination was seen in 91 placentae and abnormal histopathological features were observed in...
Numerical data is presented as mean ± standard deviation. Categorical data is presented as frequency and percent proportion with one decimal places (%).

### Table 1

Demographic and clinical characteristics of COVID-19 infected mothers included in the study (n = 173).

| Parameter                        | N (%) | Median (IQR) |
|----------------------------------|-------|--------------|
| Maternal age (years)             |       |              |
| Symptomatic patients             | 26 (15)|              |
| Severity of COVID 19             | 15    |              |
| COVID-19 diagnosis to delivery interval (days) | 0-24 | (0-2) |
| Maternal mortality               | 6 (3.5)|              |
| Singleton pregnancy              | 160 (92.5)|            |
| Twin pregnancy                   | 13 (7.5)|              |
| Mean Gestational age (weeks)     | 34.95 ± 4.29 | 36 (32.5-38.2)|

### Table 2

Details of Abnormal placental histopathological finding (N = 88).%

| Parameter                        | N | Percentage (%) |
|----------------------------------|---|----------------|
| Delayed villous maturation       | 2 | 1.2            |
| Maternal vascular malperfusion (MVM) | 50 | 27.93         |
| Villous infarction               | 33 | 18.43         |
| Central                          | 13 |               |
| Peripheral                       | 19 |               |
| Maternal floor infarction        | 1  |               |
| Increase in Syncytial knots      | 14 | 7.8           |
| RP clot/hemorrhage               | 20 | 11.17         |
| Fetal vasculopathy (FV)          | 30 | 16.75         |
| Villous Stromal-Vascular Karyorrhexis | 1  | 0.56          |
| Stem Vessel Obliteration         | 29 | 16.20         |
| Intervillous thrombi             | 1  | 0.56          |
| Villous fibrin deposits-         | 41 | 22.90         |
| Villous fibrin (extensive—≥70%)  | 7  |               |
| Villous fibrin (multifocal—30-70%) | 11 |               |
| Villous fibrin (focal—<30%)      | 23 |               |
| Acute infection                  | 12 | 6.70          |
| Chorionitis                      | 3  |               |
| Chorioamnitis                    | 7  |               |
| Subchorioamnitis                 | 2  |               |
| Chronic inflammation             | 9  | 5.03          |
| Villous fibrosis                 | 9  | 5.03          |
| Hydropic changes                 | 6  | 3.35          |
| Villous edema                    | 2  | 1.12          |
| Chorioangiiosis                  | 6  | 3.35          |
| Pseudoknot                       | 1  | 0.56          |
| Meconium staining                | 5  | 2.79          |
| Abnormal cord                    | 5  | 2.79          |
| Single umbilical artery          | 4  |               |
| Supernumerary vessels            | 1  |               |

Abbreviations: DM- Diabetes mellitus, PROM-preterm rupture of membranes, HTN- hypertension, FGR-fetal growth restriction, ICP-intrahepatic cholestasis of pregnancy, APH- Ante-partum hemorrhage, CMF- congenital malformation, NICU- neonatal intensive care unit, SGA-small for gestational age, LGA-large for gestational age, AGA- appropriate for gestational age.

### Footnotes

- a Four abortion cases with baby birth weight <500 g were excluded.
- b Out of total 179 placentae examined, four cases were <24 weeks for which the growth percentile was not available, and three were twins, in which combined placental weight was calculated for both the twin placentas. (n = 172).
- c One women out of 22 had Type II diabetes mellitus.

### Table 3

| Parameter                        | N | Percentage (%) |
|----------------------------------|---|----------------|
| Delayed villous maturation       | 2 | 1.2            |
| Maternal vascular malperfusion (MVM) | 50 | 27.93         |
| Villous infarction               | 33 | 18.43         |
| Central                          | 13 |               |
| Peripheral                       | 19 |               |
| Maternal floor infarction        | 1  |               |
| Increase in Syncytial knots      | 14 | 7.8           |
| RP clot/hemorrhage               | 20 | 11.17         |
| Fetal vasculopathy (FV)          | 30 | 16.75         |
| Villous Stromal-Vascular Karyorrhexis | 1  | 0.56          |
| Stem Vessel Obliteration         | 29 | 16.20         |
| Intervillous thrombi             | 1  | 0.56          |
| Villous fibrin deposits-         | 41 | 22.90         |
| Villous fibrin (extensive—≥70%)  | 7  |               |
| Villous fibrin (multifocal—30-70%) | 11 |               |
| Villous fibrin (focal—<30%)      | 23 |               |
| Acute infection                  | 12 | 6.70          |
| Chorionitis                      | 3  |               |
| Chorioamnitis                    | 7  |               |
| Subchorioamnitis                 | 2  |               |
| Chronic inflammation             | 9  | 5.03          |
| Villous fibrosis                 | 9  | 5.03          |
| Hydropic changes                 | 6  | 3.35          |
| Villous edema                    | 2  | 1.12          |
| Chorioangiiosis                  | 6  | 3.35          |
| Pseudoknot                       | 1  | 0.56          |
| Meconium staining                | 5  | 2.79          |
| Abnormal cord                    | 5  | 2.79          |
| Single umbilical artery          | 4  |               |
| Supernumerary vessels            | 1  |               |

Abbreviations: RP- retroplacental

- a Relative frequencies out of total 179 placentae examined.
- b A total of 173 patients were finally recruited in the study. Out of which, 13 had twin placenta. Out of 13 twin placentae, 8 were dichorionic diamniotic (DCDA), 4 were monochorionic diamniotic (MCDA), and one placenta was fused to a single mass when received by the department of pathology, thereby, choriocity could not be established. Out of 8 DCDA placenta, 5 were received in pathological department as separate placentae, therefore gross examination was done separately for each placenta. In other twin placentae, reporting was done together. Thus, 160 singleton + (13 + 5) twin placenta = 179 placenta were studied. A total of 91 placenta were studied normal from 89 mothers and 88 placentae from 84 mothers, had one or more abnormal histopathological findings.
features of fetal vascular changes. Chronic inflammation was seen in nine placentae. Villous fibrin deposition was seen in 41 placentae. Six placentae showed features of chorioangiosis. A total of five abnormal umbilical cords were observed in our study, four had two-vessel umbilical cords, and one had four-vessel umbilical cord (duplication of umbilical vein). Few other morphologic abnormalities that were observed in our study are villous edema (two placentae), delayed villous maturation (two placentae), villous fibrosis (nine placentae), pseudoknot (one placenta), and hydropic changes (six placentae). Meconium staining was seen in five placentae. Umbilical vasculitis was not noticed in our study.

3.3. Placental virology testing for COVID-19 virus

Out of 179 placentae, 15 placentae were tested for the presence of SARS-CoV-2 virus by RT-PCR testing. Only two placentae were tested positive for the SARS-CoV-2 virus. Interestingly, the morphologic examination of one of these placentae (fused DADC placenta) was normal: the twin neonates were tested negative for SARS-CoV-2 and discharged healthily. The other singleton placenta showed multifocal villous fibrin deposition and partial occlusion of stem villi. The neonate born with this placenta was also tested positive for the SARS-CoV-2 virus.
3.4. Abnormal placental morphology and clinical outcome

Table 3 demonstrates the comparison of clinical characteristics and neonatal outcomes of the COVID-19 women with normal placental histopathology (group 1, n = 89) and with abnormal placental findings (group 2, n = 81). The mean age and mean gestational age of the two groups were comparable. There was no difference in COVID-19 diagnosis to delivery interval, number of symptomatic COVID-19 mothers, and COVID-19 disease severity in the two groups. Six twin deliveries were observed in group 1 and eight twins were seen in group 2. Preterm deliveries were seen in 42 women in group 1 as compared to 48 in group 2. Comparison of clinical characteristics and pregnancy outcome of COVID-19 positive mothers with normal (N=89) and COVID-19 positive mothers with abnormal (N=81) placental morphological features.

Table 3

| Group | Maternal age (years) | COVID-19 diagnosis to delivery interval (median, IQR) | Symptomatic patients | Severity of COVID 19 | Twin gestation | Mean placental weight (grams) | Mean placental weight/baby weight (PW/BW) ratio | Gestational diabetes mellitus including type 2 DM | Preeclampsia | FGR | ICP | Abruption Placenta | Stillbirths | CMPF | Mean Baby weight (grams) | Appgar score <7 at 1 min | Appgar score <7 at 5 min | NICU admission | Male baby | SGA |
|-------|----------------------|------------------------------------------------------|----------------------|---------------------|-----------------|-------------------------------|-----------------------------------------------|-----------------------------------------------|-------------|-----|-----|----------------------|------------|-----|------------------------|------------------------|------------------------|--------------|----------|-----|-----|
| Group 1 n=89 | 29.29 ± 4.96 | 1, 0-1 days | 14 | 8 | 35.45 ± 3.95 | 471.72 ± 145.01 | 0.21 ± 0.07 | 42 | 16 | 3 | 7 | 4 | 6 | 2333.36 | 15/94 | 5/94 | 23/94 | 47/94 | 29/94 |
| Group 2 n=81 | 28.51 ± 4.74 | 1, 0-2 days | 12 | 8 | 34.44 ± 4.56 | 470.27 ± 197.08 | 0.24 ± 0.07 | 48 | 18 | 9 | 4 | 4 | 8 | 2182.36 | 26/88 | 18/88 | 27/84 | 42/88 | 34/88 |
| P value | 0.293 | 0.258 | 0.868 | 0.936 | 0.458 | 0.956 | 0.066 | 0.167 | 0.489 | 0.644 | 0.710 | 0.540 | 0.011* | 0.198 | 0.028* | 0.002* | 0.130 | 0.759 | 0.269 | 0.809 2 |
| Statistical Test applied | Independent t test (two-tailed) | Mann Whitney test | Chi square test | Chi square test | Chi square test | Chi square test | Chi square test | Chi square test | Fisher’s Exact test | Fisher’s Exact test | Fisher’s Exact test | Chi square test | Chi square test | Chi square test | Chi square test | Chi square test | Chi square test | Chi square test | Chi square test |

2. There was no significant difference in preeclampsia or gestational diabetes cases. Also, there was no difference in the number of cases of intrahepatic cholestasis of pregnancy (ICP), abruptio placenta, fetal congenital malformations, and fetal growth-restriction. The total number of male babies were also similar in both groups. The mean baby weight was also comparable in both groups. A significantly higher incidence of stillbirths was observed in group 2 in comparison to group 1 (14 vs 4, p-value 0.011). The number of neonates born with Apgar score <7 at 1 min and 5 min were also significantly higher in group 2 as compared to group 1 (Table 3). However, the total number of NICU admissions was comparable in both the groups. The number of small for gestational age babies was also similar in both the groups. The mean placental weight and PW/BW ratio was also comparable in both the groups.

3.5. Impact of abnormal placental findings on apgar score at 1 min and 5 min

The detailed statistical analysis of the relationship of abnormal placental findings and Apgar score <7 at 1 min and 5 min is shown in Table 4. The presence of villous infarction in placentae resulted in significantly lower the Apgar score at 5 min. The Apgar score at 1 min was not significantly affected by the presence or absence of villous infarction in the placenta. The relative risk of getting significantly lower Apgar score at 1 min and 5 min in the presence of RP clot/blooming was 2.61 and 3.54, respectively. The relative risk for lower Apgar score at 1 min and 5 min in the presence of intervillous fibrin deposits was 2.05 and 5.52, respectively. The other placental morphological findings like chronic inflammation, syncytial knots, acute infection, or stem vessel obliteration did not impact the Apgar score at 1 and 5 min (Table 4).

4. Discussion

Various studies describe the association of maternal covid-19 infection with placental morphology [9,15–19]. However, only a few studies mention the impact of placental morphological changes in COVID-19 infection on pregnancy outcomes [16,20]. Our study, by so far, is the first study that describes the placental morphological features in a large subgroup of COVID-19 infected mothers and correlates these findings with the pregnancy outcome of these mothers.

We studied 179 placentae delivered from 173 COVID-19 infected women with ≥20 weeks’ gestation. The incidence of placenta revealing at least one abnormal finding on histopathological examination (HPE) in COVID-19 infected mothers was 49.16%. The most common abnormal finding was maternal vascular malformation (27.93%), followed by villous fibrin deposition (22.90%), fetal vasculopathy (16.75%), and acute inflammation (6.70%). The placental abnormalities were not related to the symptoms or disease severity of COVID-19 infection. Sharps et al. analysed 20 placentae and found that MVP is seen in 46% of cases, fetal vasculopathy is seen in 35-39%, villitis in 8-7% cases, intervillitis in 5-3% of cases, and chorioamnionitis 6% of cases [10]. Shane et al. found that third trimester placentae were significantly more likely to show at least one feature of MVM, with prominent features of decidual arteriopathy including atherosis and fibrinoid necrosis and mural hypertrophy of membrane arterioles [17]. Zhang et al. in 74 placental examinations found no specific histopathological feature in the placenta for COVID-19 infection. However, they did find that mural hypertrophy had higher odds with COVID-19 infection [19]. Guleresen et al. also found no statistical difference in the histopathological changes in placentae delivered from COVID-19 infected women (n = 84), and matched non-COVID-19 infected women (n = 50) [9]. Hypertensive disorders of pregnancy are major risk factors for MVM [21,22]. The maternal vascular malperfusion can lead to FGR, preterm births, and stillbirths [12,23-25]. We did not find an increased incidence of preeclampsia or clinically detected abruptio placentae in mothers with
abnormal placental pathologies (Table 3). However, we did find increased incidences of RP clots/hemorrhages on placental morphologic examination \( n = 20 \). It can be a possibility that COVID-19 infection led to silent antepartum hemorrhages.

We also studied the outcome of neonates born to COVID-19 mothers with abnormal placental morphology and compared them with the outcomes of neonates born to COVID-19 mothers with normal placental morphology. We observed that abnormal placentae found in COVID-19 mothers led to a higher incidence of stillbirths (p-value 0.011). These stillbirths were clinically unexplainable as, they were not associated with higher incidence of pre-eclampsia, FGR, ICP, or abruptions. Also, the neonates born to COVID-19 mothers with abnormal placentas showed significant lower Apgar scores at 1 min and 5 min (p-value 0.028 and 0.002, respectively). However, NICU admissions were not affected by the presence of abnormal placental features.

Jaiswal et al. in a small comparative case-control study also studied the impact of placental injury in COVID-19 mothers \( n = 27 \) on the pregnancy outcome and found no significant impact on neonatal outcomes [20]. Rebutini et al. also didn't find any significant impact of placental changes seen in COVID-19 mothers \( n = 19 \) on their pregnancy outcome [16]. We, on the other hand, found a significant association of RP clot/hemorrhage and intervillous fibrin deposition with lower Apgar scores at 1 min and 5 min (Table 4). The increased systemic thrombotic events and microvascular injury syndrome seen in COVID-19 infection can affect the placenta leading to turbulent and slow blood flow, progressive rise in fibrin degradation products, decreased fibrinolysis and increased hypoxic-ischemic injury. Intriguingly, these placental changes can be so unpredictable and quiet, that early detection and intervention can be very difficult at times.

The major limitation of our study is the lack of comparison with non-COVID-19 controls. Thus, we cannot concretely say that the changes seen in our study are directly related to COVID-19 infection. The incidence of placental injury in COVID-19 infection in our study is nearly 50%. We agree that these changes are also seen in other pathologies and in normal cases as well and we found no effect of symptomatic/severe COVID-19 infection on the placental pathologies. Thus, it is difficult to comment regarding the exact pathophysiological changes of COVID-19 infection in our cohort. Further studies are needed to find out the effect of COVID-19 viral load on the severity of the placental injury. However, it can be postulated that it can affect the pregnancy outcomes leading to the higher incidence of silent abruptions, unexplained stillbirths, and lower Apgar scores. Therefore, vigilant antenatal and intrapartum monitoring is a must in all cases of COVID-19 infected women.

To conclude, our study is the largest descriptive-analytical research that studies the placental abnormalities in COVID-19 infection. The COVID-19 infection is associated with abnormal placental morphologic features in nearly 50% of the cases. The abnormal placental morphologies seen in COVID-19 mothers are associated with poor pregnancy outcomes. The incidence of unexplained stillbirth is significantly higher in these women. Babies born to COVID-19 mothers with abnormal placental histopathology have significantly poor neonatal Apgar scores at 1 and 5 min. Intervillous fibrin deposition and RP clots/hemorrhage are significant risk factors for lower neonatal Apgar scores at 1 min and 5 min. Villous infarctions have a significant impact on the neonatal Apgar score at 5 min. Further comparative studies are required to draw a clear conclusion regarding the impact of COVID-19 infection on placenta and its effect on pregnancy outcome.

### Ethical clearance

The institutional Ethics Committee approved the present study under the protocol number PGI/IEC/2020/001004. Written informed consent was taken from all the participants of the study.

### Funding source

None.

### Contributors

BJ and AC equally contributed to the study. BJ and AC designed and conceptualized the study. BJ helped in data collection and verified the clinical obstetric data. AC did literature search, collected the data, drafted the manuscript, performed statistical analyses. BJ, RS, and SSS helped in data collection and verified the data. BJ, RS, GRVP, VS, RB, SSS, GDP, AB, VS, RB coordinated the sample collection and recording, helped in data interpretation, and edited the manuscript. BJ, AC, and RS take responsibility for the integrity of the data and the accuracy of the data analysis, critically revised the manuscript for important intellectual content, and agreed to submit the final version for publication. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Data sharing

Restrictions apply to the availability of these data and so they are not publicly available. The data that support the findings of this study are...
available from the corresponding author upon reasonable request and with the permission of the institute.

Declaration of competing interest

We declare no conflict of interests.

Acknowledgements

We are thankful to the patients who participated in the study. We acknowledge the hard work of our residents in patient management and record keeping. We are especially thankful to Dr. Aakanksha Dogra (Senior resident, PGIMER, Chandigarh), Dr. Monish Gupta (Junior resident, PGIMER, Chandigarh), and Dr. Vaneeta Sapra (Medical social worker, PGIMER, Chandigarh) for helping us in collecting the data. We would also like to thank all the working staff of the COVID-19 ward at PGIMER, Chandigarh for their dedicated work towards patient care and specimen collection/transportation.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.placenta.2022.07.009.

References

[1] N.K. Satoskar, S. Keny, H. Bhandari, S. Marathe, N. Tilve, R. Siddarkar, J. Seal, COVID19 India tracker web app’. COVID19 India tracker. www.coronatracker.in/. (Accessed 30 July 2021).

[2] R.E. Longman, T.R. Johnson, Viral respiratory disease in pregnancy, Curr. Opin. Obstet. Gynecol. 19 (2) (2007), https://doi.org/10.1097/GCO.0b013e328028f6e7.

[3] K. Racicot, G. Mor, Risks associated with viral infections during pregnancy, J. Clin. Invest. 127 (5) (2017), https://doi.org/10.1172/JCI387990.

[4] J.K. Lee, S.-J. Oh, H. Park, O.S. Shin, Recent updates on research models and tools to study virus-host interactions at the placenta, Viruses 12 (1) (2019), https://doi.org/10.3390/v12010005.

[5] E. Antoniou, E. Orovou, A. Sarella, et al., Zika virus and the risk of developing microcephaly in infants: a systematic review, Int. J. Environ. Res. Publ. Health 17 (11) (2020), https://doi.org/10.3390/ijerph17113896.

[6] M.A. Joharsson, L. Mier-y-Teran-Romero, J. Reehuis, S.M. Gilboa, S.L. Hiles, Zika and the risk of microcephaly, N. Engl. J. Med. 375 (1) (2016), https://doi.org/10.1056/NEJMj1605367.

[7] N. Teng, D. Li, X. Wang, Z. Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thorac. Haemostasis 18 (4) (2020), https://doi.org/10.1111/jth.14768.

[8] G. Schett, M. Sticherling, M.F. Neurath, COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat. Rev. Immunol. 20 (5) (2020) https://doi.org/10.1038/s41577-020-0312-7.

[9] M. Gulersen, L. Prasaman, H. Tam Tam, et al., Histopathologic evaluation of placentas after diagnosis of maternal severe acute respiratory syndrome coronavirus 2 infection, Am. J. Obstetric. Gynecol. 2 (4) (2020), https://doi.org/10.1016/j.ajogmf.2020.100211.

[10] M.C. Sharps, D.J.L. Hayen, S. Lee, et al., A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection, Placenta (2020) 101, https://doi.org/10.1016/j.placenta.2020.08.016.

[11] L. Linehan, K. O’Donoghue, S. Dineen, J. White, J.R. Higgins, B. Fitzgerald, SARS-CoV-2 placentitis: an uncommon complication of maternal COVID-19, Placenta 104 (2021), https://doi.org/10.1016/j.placenta.2021.01.012.

[12] T.Y. Khong, E.E. Mooney, I. Ariel, et al., Sampling and definitions of placental lesions: Amsterdam placental workshop group consensus statement, Arch. Pathol. Lab Med. 140 (7) (2016), https://doi.org/10.5858/arpa.2015-0225-CC.

[13] J. Thompson, L. Ingem, R. Skjaerven, S. Rasmussen, Placenta weight percentile curves for singleton deliveries, BJOG An Int. J. Obstet. Gynecol. 114 (6) (2007), https://doi.org/10.1111/j.1471-0528.2007.01327.x.

[14] B. Almog, F. Shehata, S. Aljibari, I. Levin, E. Shalom-Paz, A. Shirim, Placenta weight percentile curves for singleton and twins deliveries, Placenta 32 (1) (2011), https://doi.org/10.1016/j.placenta.2010.10.008.

[15] J.L. Hecht, B. Quade, V. Deshpande, et al., SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers, Mod. Pathol. 33 (11) (2020), https://doi.org/10.1038/s41379-020-0639-4.

[16] P.Z. Rebuitini, A.C. Zanchettin, E.T.S. Stonoga, et al., Association between COVID-19 pregnant women symptoms severity and placental morphological features, Front. Immunol. 12 (2021), https://doi.org/10.3389/fimmu.2021.685919.

[17] E.D. Shanes, L.B. Mithal, S. Otero, H.A. Azad, E.S. Miller, J.A. Goldstein, Placental pathology in COVID-19, Am. J. Clin. Pathol. 154 (1) (2020), https://doi.org/10.1093/ajcp/aqaa089.

[18] E.T. Palberg, T. Adams, P. Rekawek, et al., Coronavirus disease 2019 infection and placental histopathology in women delivering at term, Am. J. Obstet. Gynecol. 224 (4) (2021), https://doi.org/10.1016/j.ajog.2020.10.020.

[19] P. Zhang, C. Safafia, T. Heyman, C. Safafia, S. Lederman, B. Dygulska, Detection of severe acute respiratory syndrome coronavirus 2 in placentas with pathology and vertical transmission, Am. J. Obstetric. Gynecol. 2 (4) (2020), https://doi.org/10.1016/j.ajogmf.2020.100197.

[20] N. Jaiswal, M. Puri, K. Agarwal, et al., COVID-19 as an independent risk factor for subclinical placental dysfunction, Eur. J. Obstet. Gynecol. Reprod. Biol. 259 (2021), https://doi.org/10.1016/j.ejogrb.2021.01.049.

[21] E. Weiner, O. Feldstein, L. Tamayev, et al., Placental histopathological lesions in correlation with neonatal outcome in preeclampsia with and without severe features, Pregnancy Hypertension 12 (2018), https://doi.org/10.1016/j.preghy.2018.02.001.

[22] B. Bustamante Hellfrich, N. Chilukuri, H. He, et al., Maternal vascular malperfusion of the placental bed associated with hypertensive disorders in the Boston Birth Cohort, Placenta 52 (2017), https://doi.org/10.1016/j.placenta.2021.02.016.

[23] A. Chen, D.J. Roberts, Placental pathologic lesions with a significant recurrence risk - what not to miss, APMIS 126 (7) (2018), https://doi.org/10.1111/apm.12796.

[24] R.W. Redline, Severe fetal placental vascular lesions in term infants with neurologic impairment, Am. J. Obstet. Gynecol. 192 (2) (2005), https://doi.org/10.1016/j.ajog.2004.07.030.

[25] Y.Y. Zhou, S. Ravishankar, G. Luo, R.W. Redline, Predictors of high grade and other placental histopathological lesions and the risk of microcephaly in infants: a systematic review, Int. J. Environ. Res. Publ. Health 17 (4) (2020), https://doi.org/10.3390/ijerph17040806.